McGowan G K, Baker P G
J Int Med Res. 1984;12(2):87-91. doi: 10.1177/030006058401200204.
One thousand four hundred and two patients with essential hypertension were treated by their general practitioners for 3 months with one tablet daily consisting of 200 mg acebutolol plus 12.5 mg hydrochlorothiazide: 813 were newly diagnosed and 589 were known hypertensives already on treatment. There was no 'wash-out' period before the latter changed to the study treatment. Newly diagnosed hypertensives had an average initial mean arterial pressure (MAP) of 129.9 mm Hg which fell on average by 18.2% during the study: 79% of patients had good results with final MAP levels less than 113 mm Hg (equivalent to e.g., 160/90 mm Hg), and a further 7% also had good results in that MAP fell more than 15%, another 12.5% had moderate results (falls of 5% to 15%): and only 1.5% had poor results (fell less than 5%). Known hypertensives had an average MAP of 127 mm Hg on previous treatment, which fell on average by 15.4% during this study: 70% of patients had good results with final MAP levels less than 113 mm Hg and a further 7% also had good results in that MAP fell more than 15%: 18% had moderate results and 3% poor results. Pulse rate fell by 12.5% in newly diagnosed and 10% in known treated hypertensives. If allowance is made for withdrawals due to side-effects and to the need for more than one tablet of Secadrex daily, then over all 75.7% had a good blood pressure response to study medication, 13.7% a moderate response and 10.7% a poor response. Adverse effects caused the withdrawal of 4% of newly diagnosed and 5% of treated hypertensives, predominantly nausea/vomiting, lassitude/fatigue and malaise.(ABSTRACT TRUNCATED AT 250 WORDS)
1402例原发性高血压患者由其全科医生治疗3个月,每日服用一片含200毫克醋丁洛尔加12.5毫克氢氯噻嗪的药物:813例为新诊断患者,589例为已知高血压患者且已在接受治疗。后一组患者在改用研究治疗前没有“洗脱期”。新诊断的高血压患者初始平均动脉压(MAP)为129.9毫米汞柱,在研究期间平均下降了18.2%:79%的患者效果良好,最终MAP水平低于113毫米汞柱(相当于例如160/90毫米汞柱),另有7%的患者效果良好,因为MAP下降超过15%,12.5%的患者效果中等(下降5%至15%):只有1.5%的患者效果不佳(下降不到5%)。已知高血压患者在先前治疗时的平均MAP为127毫米汞柱,在本研究期间平均下降了15.4%:70%的患者效果良好,最终MAP水平低于113毫米汞柱,另有7%的患者效果良好,因为MAP下降超过15%:18%的患者效果中等,3%的患者效果不佳。新诊断患者的脉搏率下降了12.5%,已知接受治疗的高血压患者下降了10%。如果考虑到因副作用以及每天需要服用超过一片Secadrex而退出的情况,那么总体上75.7%的患者对研究药物有良好的血压反应,13.7%的患者反应中等,10.7%的患者反应不佳。不良反应导致4%的新诊断患者和5%的接受治疗的高血压患者退出,主要是恶心/呕吐、倦怠/疲劳和不适。(摘要截选至250字)